Effects of anti-hypertensive drugs on vessel rarefaction

Current Opinion in Pharmacology

Volumn 7, Issue 2, 2007, Pages 151-157

  Battegay, Edouard J ^a   de Miguel, Lourdes Sanchez ^a   Petrimpol, Marco ^a   Humar, Rok ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 5 NITRO 2 (3 PHENYLPROPYLAMINO)BENZOIC ACID; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BEVACIZUMAB; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ICATIBANT; LOSARTAN; METOPROLOL; MIBEFRADIL; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PRAZOSIN; SPIRONOLACTONE; VALSARTAN; VASCULOTROPIN;

ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; ARTERIOLE; CAPILLARY; CAPILLARY DENSITY; CARCINOGENICITY; CLINICAL STUDY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG TARGETING; HEREDITY; HUMAN; HYPERTENSION; MICROCIRCULATION; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SKIN CAPILLARY; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD VESSELS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 33947122204     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.09.007     Document Type: Review

References (75)

1. Levy B.I., Ambrosio G., Pries A.R., and Struijker-Boudier H.A. Microcirculation in hypertension: a new target for treatment?. Circulation 104 (2001) 735-740
2. Serne E.H., Gans R.O., ter Maaten J.C., Tangelder G.J., Donker A.J., and Stehouwer C.D. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension 38 (2001) 238-242
3. Antonios T.F., Singer D.R., Markandu N.D., Mortimer P.S., and MacGregor G.A. Structural skin capillary rarefaction in essential hypertension. Hypertension 33 (1999) 998-1001
4. Humar R., Resink T.J.R., and Battegay E.J. Vascular Remodeling in Hypertension. In: Battegay E.J., Bakris G.L., and Lip G.Y.H. (Eds). Hypertension: Principles and Practice Vol 1 (2005), Marcel Dekker, New York 85-97
5. Takeshita S., Tomiyama H., Yokoyama N., Kawamura Y., Furukawa T., Ishigai Y., Shibano T., Isshiki T., and Sato T. Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res 52 (2001) 314-320
6. Gohlke P., Kuwer I., Schnell A., Amann K., Mall G., and Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension 29 (1997) 478-482
7. le Noble J.L., Tangelder G.J., Slaaf D.W., van Essen H., Reneman R.S., and Struyker-Boudier H.A. A functional morphometric study of the cremaster muscle microcirculation in young spontaneously hypertensive rats. J Hypertens 8 (1990) 741-748
8. Antonios T.F., Rattray F.E., Singer D.R., Markandu N.D., Mortimer P.S., and MacGregor G.A. Maximization of skin capillaries during intravital video-microscopy in essential hypertension: comparison between venous congestion, reactive hyperaemia and core heat load tests. Clin Sci (Lond) 97 (1999) 523-528
9. Noon J.P., Walker B.R., Webb D.J., Shore A.C., Holton D.W., Edwards H.V., and Watt G.C. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 99 (1997) 1873-1879
10. Antonios T.F., Rattray F.M., Singer D.R., Markandu N.D., Mortimer P.S., and MacGregor G.A. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart 89 (2003) 175-178
11. Pladys P., Sennlaub F., Brault S., Checchin D., Lahaie I., Le N.L., Bibeau K., Cambonie G., Abran D., Brochu M., et al. Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero. Am J Physiol Regul Integr Comp Physiol 289 (2005) R1580-R1588
12. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
13. Humar R., Kiefer F.N., Berns H., Resink T.J., and Battegay E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signalling. FASEB J 16 (2002) 771-780
14. Li W., Petrimpol M., Molle K.D., Hall M.N., Battegay E.J., and Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 100 (2007) 79
15. Tang K., Breen E.C., Gerber H.P., Ferrara N.M., and Wagner P.D. Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics 18 (2004) 63-69
16. Debbabi H., Uzan L., Mourad J.J., Safar M., Levy B.I., and Tibirica E. Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens 19 (2006) 477-483. This first observational clinical study highlights the importance of correcting the microcirculatory abnormalities in hypertension.
17. Olsen M.H., Fossum E., Hoieggen A., Wachtell K., Hjerkinn E., Nesbitt S.D., Andersen U.B., Phillips R.A., Gaboury C.L., Ibsen H., et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 23 (2005) 891-898
18. Struijker Boudier H.A., le Noble J.L., Messing M.W., Huijberts M.S., le Noble F.A., and van Essen H. The microcirculation and hypertension. J Hypertens Suppl 10 (1992) S147-S156
19. Thybo N.K., Stephens N., Cooper A., Aalkjaer C., Heagerty A.M., and Mulvany M.J. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 25 (1995) 474-481
20. Rizzoni D., Castellano M., Porteri E., Bettoni G., Muiesan M.L., Cinelli A., and Rosei E.A. Effects of low and high doses of fosinopril on the structure and function of resistance arteries. Hypertension 26 (1995) 118-123
21. Wang D.H., and Prewitt R.L. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 15 (1990) 68-77
22. Nelissen-Vrancken H.J., Boudier H.A., Daemen M.J., and Smits J.F. Antihypertensive therapy and adaptive mechanisms in peripheral ischemia. Hypertension 22 (1993) 780-788
23. Scheidegger K.J., Wood J.M., van Essen H., and Struijker-Boudier H.A. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats. J Pharmacol Exp Ther 278 (1996) 1276-1281
24. Le Noble F.A., Hekking J.W., Van Straaten H.W., Slaaf D.W., and Struyker Boudier H.A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol 195 (1991) 305-306
25. Canby C.A., and Tomanek R.J. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Physiol 257 (1989) H1110-H1118
26. Fabre J.E., Rivard A., Magner M., Silver M., and Isner J.M. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99 (1999) 3043-3049
27. Rakusan K., Cicutti N., Maurin A., Guez D., and Schiavi P. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res 59 (2000) 243-254
28. Sugawara T., Fujii S., Akm Zaman T., Goto D., Kaneko T., Furumoto T., Togashi H., Yoshioka M., Koyama T., and Kitabatake A. Coronary capillary remodeling in non-insulin-dependent diabetic rats: amelioration by inhibition of angiotensin converting enzyme and its potential clinical implications. Hypertens Res 24 (2001) 75-81
29. Silvestre J.S., Bergaya S., Tamarat R., Duriez M., Boulanger C.M., and Levy B.I. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 89 (2001) 678-683
30. Ebrahimian T.G., Tamarat R., Clergue M., Duriez M., Levy B.I., and Silvestre J.S. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 25 (2005) 65-70. This paper nicely describes the pro- and anti-angiogenic features of ACE-Is in one animal model.
31. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., Molteni A., Polverini P.J., and Bouck N.P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98 (1996) 671-679
32. Kiefer F.N., Neysari S., Humar R., Li W., Munk V.C., and Battegay E.J. Hypertension and angiogenesis. Curr Pharm Des 9 (2003) 1733-1744
33. Liu Y.H., Yang X.P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., and Carretero O.A. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99 (1997) 1926-1935
34. Siragy H.M., Jaffa A.A., and Margolius H.S. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. Hypertension 29 (1997) 757-762
35. Toblli J.E., Cao G., DeRosa G., Di Gennaro F., and Forcada P. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens 17 (2004) 172-180
36. Frisbee J.C. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 289 (2005) R307-R316
37. Kiefer F.N., Misteli H., Kalak N., Tschudin K., Fingerle J., Van der Kooij M., Stumm M., Sumanovski L.T., Sieber C.C., and Battegay E.J. Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension. Blood Press 11 (2002) 116-124
38. Kitayama H., Maeshima Y., Takazawa Y., Yamamoto Y., Wu Y., Ichinose K., Hirokoshi K., Sugiyama H., Yamasaki Y., and Makino H. Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 19 (2006) 718-727
39. Sabri A., Samuel J.L., Marotte F., Poitevin P., Rappaport L., and Levy B.I. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension 32 (1998) 371-375
40. Schieffer B., Wirger A., Meybrunn M., Seitz S., Holtz J., Riede U.N., and Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89 (1994) 2273-2282
41. Whitebread S., Mele M., Kamber B., and de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 163 (1989) 284-291
42. Seyedi N., Xu X., Nasjletti A., and Hintze T.H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26 (1995) 164-170
43. Chung N.A., Beevers D.G., and Lip G. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press 13 (2004) 183-189
44. Aravindan N., and Shaw A. Effect of furosemide infusion on renal hemodynamics and angiogenesis gene expression in acute renal ischemia/reperfusion. Ren Fail 28 (2006) 25-35
45. Guggino S., Weltin D., Chapelon D., Imbs J.L., and Stephan D. Anti-angiogenesis effects of aldosterone antagonist diuretics. Arch Mal Coeur Vaiss 95 (2002) 727-731
46. Klauber N., Browne F., Anand-Apte B., and D'Amato R.J. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation 94 (1996) 2566-2571
47. Brehm B.R., Wolf S.C., Bertsch D., Klaussner M., Wesselborg S., Schuler S., and Schulze-Osthoff K. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 49 (2001) 430-439
48. Keledjian K., Garrison J.B., and Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 94 (2005) 374-388
49. Pan S.L., Guh J.H., Huang Y.W., Chern J.W., Chou J.Y., and Teng C.M. Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 169 (2003) 724-729
50. Ichioka S., Shibata M., Kosaki K., Sato Y., Harii K., and Kamiya A. In vivo measurement of morphometric and hemodynamic changes in the microcirculation during angiogenesis under chronic alpha1-adrenergic blocker treatment. Microvasc Res 55 (1998) 165-174
51. Fulgenzi G., Graciotti L., Collis M.G., and Hudlicka O. The effect of alpha 1 adrenoceptor antagonist prazosin on capillary supply, blood flow and performance in a rat model of chronic muscle ischaemia. Eur J Vasc Endovasc Surg 16 (1998) 71-77
52. Miura S., Fujino M., Matsuo Y., Tanigawa H., and Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 28 (2005) 147-153
53. Kumamoto H., Okamoto H., Watanabe M., Onozuka H., Yoneya K., Nakagawa I., Chiba S., Watanabe S., Mikami T., Abe K., et al. Beneficial effect of myocardial angiogenesis on cardiac remodeling process by amlodipine and MCI-154. Am J Physiol 276 (1999) H1117-H1123
54. Manolopoulos V.G., Liekens S., Koolwijk P., Voets T., Peters E., Droogmans G., Lelkes P.I., De Clercq E., and Nilius B. Inhibition of angiogenesis by blockers of volume-regulated anion channels. Gen Pharmacol 34 (2000) 107-116
55. Rodriguez-Porcel M., Zhu X.Y., Chade A.R., Amores-Arriaga B., Caplice N.M., Ritman E.L., Lerman A., and Lerman L.O. Functional and structural remodeling of the myocardial microvasculature in early experimental hypertension. Am J Physiol Heart Circ Physiol 290 (2006) H978-H984
56. Zhu X.Y., Daghini E., Chade A.R., Rodriguez-Porcel M., Napoli C., Lerman A., and Lerman L.O. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol 26 (2006) 1746-1752
57. Sane D.C., Anton L., and Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 7 (2004) 193-201
58. Felmeden D.C., Spencer C.G., Belgore F.M., Blann A.D., Beevers D.G., and Lip G.Y. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16 (2003) 11-20
59. Prior B.M., Yang H.T., and Terjung R.L. What makes vessels grow with exercise training?. J Appl Physiol 97 (2004) 1119-1128
60. Jesmin S., Hattori Y., Togashi H., Ueno K., Yoshioka M., and Sakuma I. Age-related changes in cardiac expression of VEGF and its angiogenic receptor KDR in stroke-prone spontaneously hypertensive rats. Mol Cell Biochem 272 (2005) 63-73
61. Feihl F., Liaudet L., Waeber B., and Levy B.I. Hypertension: a disease of the microcirculation?. Hypertension 48 (2006) 1012-1017
62. Banfi A., von Degenfeld G., and Blau H.M. Critical role of microenvironmental factors in angiogenesis. Curr Atheroscler Rep 7 (2005) 227-234
63. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
64. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
65. Yoshiji H., Kuriyama S., Noguchi R., and Fukui H. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 4 (2004) 555-567
66. Yasumatsu R., Nakashima T., Masuda M., Ito A., Kuratomi Y., Nakagawa T., and Komune S. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 130 (2004) 567-573
67. Lever A.F., Hole D.J., Gillis C.R., McCallum I.R., McInnes G.T., MacKinnon P.L., Meredith P.A., Murray L.S., Reid J.L., and Robertson J.W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 352 (1998) 179-184
68. Ignoffo R.J. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 61 Suppl 5 (2004) S21-S26
69. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., Langer C.J., DeVore III R.F., Gaudreault J., Damico L.A., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
70. Morbidelli L., Parenti A., Giovannelli L., Granger H.J., Ledda F., and Ziche M. B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br J Pharmacol 124 (1998) 1286-1292
71. Parenti A., Morbidelli L., Ledda F., Granger H.J., and Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 15 (2001) 1487-1489
72. Knox A.J., Corbett L., Stocks J., Holland E., Zhu Y.M., and Pang L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J 15 (2001) 2480-2488
73. Thuringer D., Maulon L., and Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 277 (2002) 2028-2032
74. Munzenmaier D.H., and Greene A.S. Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density. Am J Physiol Heart Circ Physiol 290 (2006) H512-H516
75. Forder J.P., Munzenmaier D.H., and Greene A.S. Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. Am J Physiol Heart Circ Physiol 288 (2005) H1989-H1996